A skilled team of investment professionals and volunteers with diverse knowledge in science, healthcare and technology.Meet The Team
How We Invest
A holistic approach with the added benefits of the knowledge and resources of our parent company, JDRF.Learn More
News and Press
Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced ThrombocytopeniaFrederick, Md – June 13, 2022 – Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat serious immuno...
By using a venture philanthropy model, the T1D Fund is uniquely positioned to create an investment market in T1D.
[The Fund] is different because it's looking for viability and commercial uptake whereas a basic research grant is just about the learning. To advance the mission of JDRF we need both.